Nurix Therapeutics (NASDAQ:NRIX) Given “Buy” Rating at Needham & Company LLC

Posted by Max Byerly on Jul 11th, 2026

Needham & Company LLC reiterated their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $34.00 price target on the stock.

A number of other research analysts have also recently weighed in on NRIX. Truist Financial lifted their price target on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 8th. HC Wainwright boosted their price objective on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Company downgraded shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $28.00 to $25.00 in a research report on Monday, June 8th. Jefferies Financial Group increased their price target on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $33.77.

Check Out Our Latest Report on Nurix Therapeutics

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded down $1.63 during trading on Friday, reaching $23.06. The company had a trading volume of 1,552,950 shares, compared to its average volume of 2,287,902. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -7.30 and a beta of 1.80. Nurix Therapeutics has a 12-month low of $8.19 and a 12-month high of $25.08. The stock’s 50 day moving average price is $18.44 and its two-hundred day moving average price is $17.37.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). The company had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 73.57%. As a group, research analysts expect that Nurix Therapeutics will post -2.88 earnings per share for the current year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of Nurix Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the sale, the insider owned 115,005 shares of the company’s stock, valued at $2,300,100. The trade was a 4.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at approximately $624,027.20. The trade was a 27.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 25,051 shares of company stock worth $434,466. 6.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Nurix Therapeutics during the fourth quarter worth $33,000. KBC Group NV acquired a new stake in Nurix Therapeutics during the 1st quarter worth about $34,000. Finally, Wexford Capital LP acquired a new position in shares of Nurix Therapeutics in the third quarter worth about $41,000.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Roche collaboration news was a major catalyst: Nurix said it entered a global partnership for bexobrutideg with potential total payments of up to $2.3 billion, including a $700 million upfront payment. Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Positive Sentiment: Royal Bank of Canada raised its price target on Nurix Therapeutics from $30 to $33 and reiterated an outperform rating, signaling confidence in upside from current levels.
Positive Sentiment: Stifel Nicolaus lifted its target from $34 to $40 and maintained a buy rating, while Needham and BTIG also reaffirmed buy ratings with targets of $34 and $32, respectively, adding to the bullish analyst tone.
Neutral Sentiment: Nurix reported second-quarter 2026 results with an EPS loss of $0.81 and revenue of $9.04 million, both below estimates, which kept focus on the company’s pipeline and partnership potential rather than near-term fundamentals. Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Negative Sentiment: The earnings miss may cap enthusiasm somewhat, as the company posted a wider loss than expected and revenue came in well below consensus. Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.